Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Farm Animals is big .. Livestock is big business .. if we can get a Truforma in the hands of current 1,500 clients of this company is gold.. basically sponsored Truforma placement making money via cartridge sales is genius why not take a free Truforma ?
This company brings in 5 million annually which means 1.25 million each quarter for us.. going long and loading up is the best bet always worked well for me.. 59 cent was the next support building level like 49 cents was.. this will continue up to a $1 which is the next support building area.
Morning
Zomedica Acquires PulseVet
October 1, 2021 - 6:01 am
ANN ARBOR, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that it had acquired the Pulse Veterinary Technologies businesses for $70.9 million in an all-cash, stock transaction.
Pulse Veterinary Technologies (“PulseVet”) is a world leader in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients. The high-energy sound waves stimulate cells and release healing growth factors in the body that reduce inflammation, increase blood flow, and accelerate bone and soft tissue development. PulseVet’s technology is used in conditions including tendon and ligament healing, bone healing, osteoarthritis, chronic pain, and wound healing.
The PulseVet business employs a razor-razorblade economic model in which a customer buys a shock wave generator as capital equipment, along with replaceable therapy hand pieces called “Trodes.” Each Trode has an expected life of forty to fifty therapy sessions. Once a Trode completes its useful life, the customer replaces it with a refurbished Trode.
PulseVet is currently the market leader in the equine space with 1,500 systems actively in use globally. It recently launched a new handpiece, the X-Trode, which has an energy output intended for maximum efficacy while no longer requiring patient sedation.
Robert Cohen, Chief Executive Officer of Zomedica, commented, “As previously indicated following our fundraising efforts and the establishment of a business development capability, it has been our goal to complement our TRUFORMA® product platform, and to accelerate the growth of Zomedica overall, by strategically investing to expand our product offerings, technologies, and product development efforts. This selective process, focused on expanding Zomedica’s capability to be a valued partner to the veterinary clinic by bringing novel and valuable offerings that enhance both animal and veterinary practice health, has led us to PulseVet.”
“During our extensive due diligence process, we consistently were impressed by both the strength of the PulseVet team led by Adrian Lock and the solid business that they have built. We believe that this acquisition will enable us to enhance both of our organizations by what we learn from each other and add to the combined effort. Among other things, we expect that our existing sales organization will add PulseVet’s small animal products to its product portfolio to help accelerate the growth of the X-Trode. On behalf of everyone at Zomedica, I would like to extend a hearty welcome to the entire PulseVet team.”
PulseVet CEO, Adrian Lock, added, “We are extremely pleased to be joining the Zomedica team and particularly excited to continue building on the early momentum of our new X-Trode handpiece to accelerate the utilization of shock wave therapy in the companion animal market.”
Stifel acted as exclusive financial advisor and Maslon LLP acted as legal advisor to Zomedica in this transaction.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
News should hit on or after OCT 11th
Excuse me, dinner was last night not last week
https://pasteboard.co/nkGeynsH3p46.png
Never had to cut losses anywhere made up for them else where.. while continually buying the dip always worked in my favor!
Wrong they actually had 60 units sold as of last quarter probably surpassing sales of last quarter in Q4, and im hearing they closed a deal with a Big Vet Corp with 400+ Offices in the Long Island dinner last week. 2 assays to released in Oct with 3 following before end of the year. Global sales kicking in 2022 as well.
as you can see in the chart ZOM is at a very strong support level and they should not lose it now.
I expect it to start raising toward the green lines.
https://www.tradingview.com/chart/ZOM/2E4r9Gxk-ZOM-at-support/
Never mind found it someone was trying to fluff up the facts of loss to make it sound good on Stocktwits smh
Hey bro can repost the 10Q where you got that 14 million loss on cocaine and hookers.
Sounds like a rant
Smells like a buy out will happen here soon if not def a M/A
1/2 cents down is a crash apparently
Cocaine and hookers what else can you spend millions on ??
did y’all see the Zoom news today on CNBC? Their latest acquisition target was flagged for now by the Feds due to Chinese interest
Huge news.
Microsoft tried buying Zoom Inc. not once BUT twice .. New report is detailing
Then Google follows up and tries buying Zoom after Microsoft failed
Out of blue CEO Mark wins $9.7 million lawsuit against Microsoft with 10K showing secret agreement for $9.7 million
Then Reg A for $2.5 to help launch SafeVchat
Then smoke screen Reg A for $7.5 million which gets cancelled
Going into October this is starting to feel more of bear trap then anything.. news will flowing in this fall.. 2 assays are supposed to drop end of September beginning of October.. get your bag.. zombies don’t die
Hope y’all got your bags ready! Fox News & Bloomberg next .. as said in the last interview.
“With this latest investment, we believe StrikeForce has enough monies to now expand on its existing corporate growth strategy, and hire additional sales, marketing and the technical people required to capitalize on the timing and competitive advantage that we have in the authentication, endpoint security & Video collaboration spaces. Collectively, in our estimation, these three technologies are expected to exceed an aggregate of $100B in sales by 2026, and we appear, in our opinion, to be the only cyber security company in the market addressing all three areas, and with patented products,”
“In contrast, from the very beginning, we architected SafeVchat™ to be able to address applications like this. As a result of that, our first API customer, we expect, will be rolling out SafeVchat™ to over 2800 locations for a Fortune 100 company shortly. The great thing for StrikeForce is that we collect revenues on multiple users, per location, per month. Our customer also has many other companies that they plan on rolling it out to as well. Stay tuned,”
“With this latest investment, we believe StrikeForce has enough monies to now expand on its existing corporate growth strategy, and hire additional sales, marketing and the technical people required to capitalize on the timing and competitive advantage that we have in the authentication, endpoint security & Video collaboration spaces. Collectively, in our estimation, these three technologies are expected to exceed an aggregate of $100B in sales by 2026, and we appear, in our opinion, to be the only cyber security company in the market addressing all three areas, and with patented products,”
Coincidence I think not!
You have to admire the corrupt manipulators in the market for the way the stick the finger to retail. As shown in the offering dated May 11, the price of record day of close when papers were filed April 22nd was .064.
Today close of bell price is .0646....and we know offering is closing any day....possibly tomorrow.
$ZOM Due Diligence
——————————————————————————
CEO Robert Cohen Track Record
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163198942
——————————————————————————
Razer Blade System in Sales
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163198928
——————————————————————————
Cartridge Prices
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163198914
——————————————————————————
Head of Commercialization Sales
Zomedica utilizing it's competitors knowledge.... It's nice to have a high-level person from one of Zomedica's biggest competitors on our team...
Bruk Herbst - Zomedica’s Chief Commercial Officer
Notable Experience:
1. IDEXX - Executive Director, Head of Sales and Marketing
2. Voyce - Executive, Sr. Vice President of Sales Marketing
3. CSL, Sales Consulting - Founder
(IDEXX is our main competitor in the market, check them out)
"Over the course of his dynamic career, he has successfully launched numerous veterinary products on behalf of global corporations and startup enterprises.".
—————————————————————————
Zomedica has $277.0+ Million on hand... and is set to Acquire... but who?! Learn: beechwood.pro/brochure.pdf
"As part of our business strategy, we may pursue in-licenses or ACQUISITIONS of other complementary assets and business and may also pursue strategic alliances."
-10-K Earnings 2020
---Robert Cohen's (CEO) specialties include acquisitions and global expansion within industry! Even while he is acting CEO of Zomedica, he remains a Senior Advisor for Beechwood Capital Advisors.
"Beechwood's team has deep experience in commercial banking, investment banking and management consulting... ...We have managed acquisitions, mergers, divestitures, business sales and financial transactions for companies valued between $5 million and $350 million dollars.
Our Advisory Board consists of many well-known executives and recognized experts in their respective fields, including Robert Cohen, Jack Jacobs, Don Jones, and Henry DeGeneste."
——————————————————————————
1. Series 1 Shares Eliminated, opening the door to amalgamations, mergers, acquisitions etc.
2. Cohen Specializes in Acquisitions!
3. Cohen is still a Senior Advisor of Beechwood, specializing in acquisitions!
4. Cash-on hand & no debt + new revenue is a great incentive. It's like buying a car made of gold, if it doesn't run, you can still sell the gold no problemo.
5. Price volatility and extreme short interest. Hard to deny the heavy manipulation here.
6. Lack of PR. This could be to keep the price down, or it could just be because it doesn't matter if they're being bought.
7. Overly bearish sentiment for there being no bad news, and tons recent and potential good news
——————————————————————————
Zomedica's Partners:
Qorvo owns 2,565,789 shares at $1.52
Seraph owns 641,717 shares at $1.94
Celsee owns 112,314 shares at $2.22
Previous Series 1 Shareholders:
?Wickfield owns 24,719,101 shares at $1.78
Wickfield Bridge Fund LLC, previously held 12 Series 1 Preferred Shares.
Each of those shares cost them $1.0m (totaling $12.0m). They were guaranteed a return of $108.0m either through direct payment or 9% royalty of ZOM's net sales.
Instead, Wickfield Bridge Fund LLC agreed to exchange their 12 Series 1 Preferred Shares for 24,719,101 common shares at 1.78 per share, totaling ~$44.0m.
This means that Wickfield Bridge Fund LLC decided to "forfeit" $64.0m dollars of guaranteed profit in order to receive their common shares at $1.78 per share.
For Wickfield Bridge Fund LLC to "break even" the share price must reach a minimum of $4.36...
——————————————————————————
Bought Deal:
H.C. Wainwright 105,013,158 shares at $1.90
——————————————————————————
"In early 2020, we successfully COMPLETED the development and manufacturing milestones for our liquid biopsy platform..... We intend to seek one or more partners for the further development and commercialization of the liquid biopsy platform."
10-K Filing, February 26th 2021
——————————————————————————
"Following the commercial launch of TRUFORMA, we expect to continue the development of another point-of-care diagnostic platform..... [ZM-020] ...... This platform is being developed with Seraph Biosciences, Inc....."
-10-K Filing, February 26th, 2021
——————————————————————————
Using the expected YoY growth rate increase from Year 2 and 3 (which was 29%) in the PCG Report, we could potentially see revenue in the billions by Year 6. The below chart is found in the June 25th PCG Research Report and only projects years 1-3.
We have no way of knowing what the actual growth rate will be. However, since years 2 & 3 were the only projected revenue [post launch] shared by Zomedica and PCG. We can use it to project at least something.. So, years 4-8 are assumed to increase in growth by 29%, just like Zomedica expected year 2-3 revenue to grow.
This is likely a low estimate, considering Zomedica's growth goals are global.
Year 1: $7,450,000
Year 2: $20,250,000
Year 3: $60,750,000.00
Year 4: $156,735,000.00
Year 5: $449,829,450.00
Year 6: $1,421,461,062.00
Year 7: $4,904,040,663.90
Year 8: $18,341,112,082.99
——————————————————————————
Pipeline
* ZM-024 (TRUFORMA) - PoC Biosensor Platform // Thyroid & Adrenal Disorder Immunoassays +3 additional assays + 2 more by end of year.
* ZM-022 - Lymphoma Assay
* ZM-020 - PoC Pathogen Detection Platform // Urine & Fecal Testing
* ZM-017 - Canine Cancer Liquid Biopsy Platform // Hemangiosarcoma, Osteosarcoma & Lymphoma
* ZM-012 -Metronidazole Tablet // Anti-diarrheal - Approved for use in humans, same API as Flagyl
* ZM-011 - Transdermal Fluoxetine // Behavioral disorders, e.g. inappropriate urination, same API as Prozac
* ZM-007 - Metronidazole Oral Suspension // Anti-Diarrheal for small breeds & puppies.
* ZM-006 - Transdermal Methimazole // Hyperthyroidism - Oral formulation approved for use in humans (Tapazole) & cats (Felimazole)
——————————————————————————
Institutional Shares - 149,363,921 - 15.30%
Vanguard Holds 82,747,393
State Street Corp Holds 18,366,408
BlackRock Holds 17,325,384
Renaissance Technology Holds 13,371,960
SPDR S&P Pharmaceuticals ETF Holds 13,091,502
Cambridge Investment Holds 11,143,288
Geode Capital Management Holds 7,881,629
FSMAX Fidelity Holds 7,285,929
ProShares Pet Care ETF Holds 3,974,156
Brown Brothers Harriman Holds 2,285,532
Northern Trust Holds 2,157,655
Morgan Stanley Holds 1,990,890
Swiss National Bank Holds 1,983,700
Chase Bank Holds 1,115,014
Pinnacle Wealth Holds 1,005,022
iShare S&P Total US Market 900,203
Dr. Jane Eagleson was appointed as Independent Director of the Company.
A veterinarian with more than 30 years of experience in animal health pharmaceutical development, Eagleson is currently Vice President of Clinical and Regulatory Affairs at Nexvet Biopharma, a veterinary biotherapeutics company. She concurrently serves, since January 2013, as owner of Bleecker Street Consulting, an animal health consulting firm that specializes in pharmaceutical development strategy in North America, Europe and the Oceania markets. From September 2007 through December 2012, Eagleson held various leadership positions with Argenta, a pharmaceutical contract research and contract manufacturing organization. She joined Argenta as Head of Clinical Research and Development and elevated to Head of Growth Strategies where she assumed overall ownership of the company strategic plan. Prior to that, Eagleson served in several senior director roles with Pfizer, Inc. from December 1999 through February 2007, leaving the company as Senior Director of Asian Business Development where she was based in India and responsible for strategic planning and execution of Asian business initiatives for both animal health and human health organizations. Before Pfizer, Eagleson was a Director with Merial from 1991 to 1997 and served as Research Veterinarian with Merck Animal Health from 1985 to 1991. She has a Master of Veterinary Science in immunology from Massey University and Bachelor of Veterinary Science from the University of Sydney. She has also authored more than 35 publications in peer reviewed journals.
Mr. James LeBar is Independent Member of the Company. aka Mr. negative to positive cash flow in under 12 months
He has more than 40 years of experience as an entrepreneur and executive leader, James Jim LeBar is an expert in building and operating startup companies and establishing corporate structures for profitability and success. He served as president and CEO of numerous Canadian companies and was founder and operator of the largest importer of seafood products in North America. His supreme talent for sales and customer service have directly contributed to profitable market expansions for enterprises throughout North America. Most recently serving as a turnaround consultant for a specialized health training company, Jim transformed operations and established realistic sales goals, taking the company from negative to positive cash flow in under 12 months. His consulting experience further complements his accomplished background in investor and customer communications and regulatory compliance specific to imports and exports.
Mr. Jeff Rowe is Independent Member of the Company.
He has over 30 years of experience in the specialty pharmacy industry, Jeff Rowe most recently served as Executive Vice President and board member of Diplomat Inc., the largest independent specialty pharmacy company in the United States. During his tenure with Diplomat, the company grew from a single location with less than US5 million in revenue, to 16 locations and US3 billion in sales, and became publicly traded on the New York Stock Exchange. Prior to that, Jeff owned two successful community pharmacies in Genesee County, Michigan. An authority in pharmaceutical operations, Jeff offers critical insights into fundamental business strategies involving accreditation, contracting, cybersecurity and regulation, combined with an expertise in compounding and integrative medicine. He is uniquely qualified to identify process improvements and efficiencies while maintaining compliance and quality standards, for increased revenue, profitability and customer satisfaction. Jeff holds a Bachelor of Pharmacy degree from Ferris State University and has completed many healthrelated credential courses.
Mr. Gerald L. Solensky is Executive Chairman of the Board, President
He is determined to revolutionize the animal health industry by building an unprecedented business model alongside a world class leadership team. With a 20year track record building successful operations within startup, turnaround and rapid change environments, Gerald is committed to helping animals by ensuring the success of the veterinarians who care for them. Gerald began his career with Yamaha Motors as the youngest executive to command national and international accounts averaging US50 million in total sales. He entered the banking industry serving as Regional Vice President of Fifth Third Bank, where he managed US250 million portfolio, and subsequently as Senior Vice President at IndyMac Bank where he managed the PL statement in the mortgage backed security division. Before joining Zomedica, Gerald served as Director, President and CEO at Dynamic Fuel Systems, a TSXV listed fuel system technology firm. Most recently, Gerald completed over 800 observation hours in pre veterinary medicine to garner a more complete understanding of Zomedicas veterinary customer and their associated needs.
Ms. Angie Moricz is Executive Administrative Assistant of the Company.
She brings more than 20 years of professional experience to the Zomedica team, having served in administrative leadership roles for organizations including Ducks Unlimited, Glacier Hills, Dawn Food Products and ADP to name a few. A master of budgetary controls, Angies approach to office and facility management has resulted in cost savings nearing 50 percent with contract vendors and suppliers and overall reductions in fiscal year budgets. She has also served a primary role in authoring documentation and procedures for ISO 900110027, SAS 70, and SOX.
Ms. Angy Guerrant is Director of Portfolio Management of the Company.
She has built her 15year career on the foundation of successfully leading corporate business initiatives that directly impact the bottom line. During her tenure with MPI Research, she increased annual revenue by US9.6 million by establishing and enforcing key policies while capturing scope changes impacting budgets. She quickly established a reputation for expertly sourcing and forecasting capacity over a diverse project portfolio, managing 544 research rooms and over 700 employees across 1, 800 active projects with durations ranging from months to years. She is an ace in all levels of procurement including vendor evaluation and selection and has served as the primary line of support for sales teams throughout the United States, Europe, and Asia Pacific regions. Angy earned her BS in biomedical science from Western Michigan University and is a Certified Laboratory Animal Technologist.
Mr. Shameze Rampertab is Chief Financial Officer, Executive Member of the Company.
He is a seasoned financial leader in the healthcare sector with 20 years of experience, Shameze is a master of capital markets, strategic planning and financial analysis. Over the course of his distinctive and accomplished career, he successfully served as chief financial officer for multiple publicly traded healthcare startups, worked as an investment banker, thrived as a sellside healthequity research analyst, and raised over 480 million of private and public capital. Before joining Zomedica, Shameze served as CFO and secretary at Profound Medical Corporationration where he spearheaded a Qualifying Transaction with a Capital Pool Corporationrationration resulting in the listing of shares on the TSX Venture Exchange. Prior to that, he was CFO and Vice President of Finance for Intellipharmaceutics International Inc., a NADSAQ and TSX listed pharmaceutical company. He received his chartered professional accountant and chartered accountant designations from the Canadian Institute of Chartered Accountants after earning his MBA from McMaster University and BS in molecular genetics and molecular biology from the University of Toronto.
Age: 52 CEO Since 2020 CPA
734 369 2555 http://www.zomedica.com
Dr. William Carpenter MacArthur, MS, DVM, is Executive Director and Chief Medical Officer, Director of Research and Development of the Company.
He brings a breadth and depth of clinical knowledge and animal biotechnology expertise to his role. He founded GeneWorks, a small cap biotechnology startup based on his discovery of a method for expressing large quantities of human protein into the egg whites of transgenic hens. He served as CEO and Institutional Veterinarian for the firm, which established a postmoney valuation of US35 million. He presently owns and operates a sixdoctor small animal clinical practice, where he particularly enjoys solving difficult diagnosis challenges
734 369 2555 http://www.zomedica.com
MacArthur earned BS degrees in zoology, biochemistry, and chemistry from the University of Massachusetts Amherst, a MS in cellular and molecular biology from the University of Michigan, and doctor of veterinary medicine from Michigan State University.
Mr. Rodney J. Williams aka Capitan Growth CEO for an Investment Firm in Emerging Companies
He's an Independent Member of the Company. He has over 20 years of medical technology and related healthcare experience, Rodney Rod Williams successfully guided both large and small cap companies through growth cycles, while strengthening product portfolios and boosting commercial planning competencies. He is an entrepreneur residence with PTV Healthcare Capital, a private equity investment firm known for transforming early and middle market companies into efficient and diversified businesses with superior growth profiles. Rod is the former President and CEO of Heart Rhythm Society Consulting Services where he established specific business services to improve the operating performance and profitability of hospitals, integrated delivery networks, and cardiology practices. He also served in senior executive positions with St. Jude Medical, GE Healthcare, Johnson and Johnson, and Bausch Lomb. Rod earned his MBA and BS degree from the University of Southern California and attended the General Management Executive Leadership Program at The Wharton School of Business.
MBA
734 369 2555 http://www.zomedica.com
Mr. Tom Robitaille aka Mr. Global Sales Advisor
He was appointed as Independent Director of the Company. A results focused international business leader with 30 years of animal health experience, Robitaille is currently Vice President of Veterinary Channel Development at Blue Buffalo Company, a premium, all natural pet food company. Prior to that, Robitaille held various director level and senior management positions during his 19year career with the animal health pharmaceutical company Vetoquinol SA Inc. Robitaille was the Americas Group Director from September 2006 through October 2015, where he managed affiliates and regional distributors in Canada, USA, Mexico and Brazil. From October 2004 to October 2006 he was responsible for veterinary pharmaceutical operations in the United Kingdom, Ireland, Belgium, and the Netherlands as Managing Director. He also served as Director of International Development from October 2001 through September 2004, where he contributed to an increase in sales and profit in Eastern Europe, Asia Pacific, Africa, and Latin America. Before Vetoquinol, Robitaille was a Product Manager with Elanco, the animal health division of Eli Lilly and Company, and prior thereto, started his animal health career serving in various sales and marketing positions throughout Canada, USA, Europe and the Middle East with Sandoz, a generic pharmaceuticals company. Robitaille has a MBA from the University of Warwick and BS degree from Concordia University.
Director Since 2016 MBA
734 369 2555 http://www.zomedica.com
Mr. Bruk Herbst Zomedica CCO
He was appointed as Chief Commercial Officer of the Company, with effective from July 10, 2017. Herbst brings with him more than 20 years of experience leading commercial strategies to drive sales, marketing, support and technical teams to achieve accelerated revenue growth, lasting customer relationships and industry leading results, in particular leading the successful launch of an extensive number of products for the veterinary industry. He will lead the commercial strategic launch for Zomedica diagnostic, point of care and therapeutic product offerings. Prior to joining Zomedica, Herbst was the Executive Senior Vice President of Sales and Marketing at i4C Innovations. Before that, he served as Executive Senior Director and Head of U.S. Sales at IDEXX Laboratories, where he was responsible for inclines and reference lab diagnostics, point of care solutions, and information technologies and digital radiography solutions. Herbst also held commercial leadership roles in patient monitoring, pharmacy and diagnostics with Omnicare Specialty Care Group and Life Systems. He holds a BS in business from the University of Arizona.
Executive Since 2017
734 369 2555 http://www.zomedica.com
Dr. Johnny D. Powers Zomedica Sales Advisor Board Member
He is Independent Director of the Company. Dr. Powers has more than 30 years of experience in the medical diagnostics industry, including over seven years of experience in veterinary healthcare as a senior executive at IDEXX Laboratories. Dr. Powers was Executive Vice President of IDEXX from July 2012 until February 2016, overseeing multiple business units, including IDEXX Reference Labs, Telemedicine Services, Rapid Assay PointofCare Products, Bioresearch and Worldwide Operations. He joined IDEXX as Corporation Vice President in February 2009, where he led IDEXX Reference Labs to a global leadership position. Prior to joining IDEXX, Dr. Powers was Vice President responsible for the Cancer Diagnostics business of Becton, Dickinson and Company, a medical technology company, from January 2007 to June 2008. Dr. Powers joined Becton, Dickinson and Company as a result of its acquisition in December 2006 of TriPath Imaging Inc., a molecular diagnostics based cancer diagnostics company, where he held various senior management positions from November 2001 to January 2007, including Vice President of Worldwide Operations, and President of the TriPath Oncology business unit. From February 1996 to September 2001, Dr. Powers was employed by Ventana Medical Systems, Inc., a tissue based cancer diagnostics company, where he held various positions, including Vice President and General Manager of the Anatomical Pathology business and Vice President and General Manager of Worldwide Operations. From June 1990 to February 1996, Dr. Powers was employed by Organon Teknika Corporation, a medical diagnostics company, in various technical management roles
Age: 57 Director Since 2019 MBA
734 369 2555 http://www.zomedica.com
Powers holds a bachelor’s degree in chemistry from Wake Forest University, an M.S. in chemical engineering from Clemson University, an M.B.A. from the Duke University Fuqua School of Business and a Ph.D. in biochemical engineering from North Carolina State University.
Reversal Uptrend
Support 6 Cents
Hit 13 Cents
Support 9 Cents
Hit 17 Cents
Support 11 Cents
Hit 20 Cents
Support 15 Cents
Hit 27 Cents
Support 22 Cents
Hit 49 Cents
Support 38 Cents
Hit 60 Cents
Manipulated
Support 35 Cents
Hit $1
Reversal Uptrend
Support 77 Cents
Hit $1.25
Support $1.05
Hit $1.47
Support 80 Cents
Hit $2
Support $1.75
Hit $2.30
Support $2.07
Hit $2.90
Manipulated
Support $1.35
Hit $2.74
Reversal Uptrend
Support $2.07
Hit $2.99
Manipulated
Support 75 Cents
Hit $1.30
Support 70 Cents
Hit $1.05
Reversal Uptrend
Support 44 Cents
Hit 80 Cents
Support 54 Cents
Hit ???